Entity

KRAS

A gene frequently mutated in cancers; long considered 'undruggable' until recent targeted therapies.

As of 10 Nov 2026Last evidence 9 Nov 2026

What is happening now

  • Sotorasib plus panitumumab extends progression-free survival in KRAS G12C-mutant colorectal cancer

    Reported claim · first reported 7 Nov 2026 · 1 claim · best-carried claim: 1 separate publisher

  • How Does Divarasib Compare With Other KRAS Inhibitors in NSCLC? - Targeted Oncology

    Reported claim · first reported 5 Nov 2026 · 1 claim · best-carried claim: 2 separate publishers

  • Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC - OncLive

    Reported claim · first reported 4 Nov 2026 · 1 claim · best-carried claim: 2 separate publishers

All 3 events and claims involving KRAS

What changed

  • Attention Fading: 11 mentions on 10 Nov 2026, against 12 on 20 Oct 2026 (-8%).
  • State No change in coverage state or wire tier recorded since 4 Nov 2026.
  • Claims No claim first reported since 9 Nov 2026.

How well we know this

539 documents · 189 publishers · 7% say something specific about it · last evidence 9 Nov 2026

  • Gap: 7% of mentions say something specific about it; the rest only name it
  • Gap: 5 receipts withheld: no source link (the same rule the topic record applies)

In this snapshot’s daily coverage:

Reported alongside KRAS

Names most often reported alongside it; bigger circles and heavier lines mean more shared documents. A dashed circle has no page of its own yet.

Colorectal Canc…ImmunotherapyKras-Mutant
  • Colorectal Cancer · 195 shared documents
  • Lung Cancer · 139 shared documents · no page of its own yet
  • G12d · 96 shared documents · no page of its own yet
  • Immunotherapy · 76 shared documents
  • Kras-Mutant · 67 shared documents
  • Egfr · 56 shared documents · no page of its own yet
  • Cancer Cells · 51 shared documents · no page of its own yet
  • Braf · 45 shared documents · no page of its own yet
  • Tp53 · 42 shared documents · no page of its own yet
  • ctDNA · 37 shared documents · no page of its own yet

Story momentum

Fading

The word compares 11 mentions on 10 Nov 2026 with 12 on 20 Oct 2026 (-8%); a change of less than 8% either way reads Steady.

Daily mentions -52% from 27 Sept 2026 to 10 Nov 2026, between 5 and 42 a day

How often tracked coverage mentions KRAS, day by day.

Market price, cited

Not priced yet

No open prediction market prices a question materially about KRAS yet. Ask about KRAS

No market price on file: no prediction market prices a question about this name yet

Coverage volume and market price are separate measures.

For developers

This page is also an object: GET https://sigb.ai/api/v1/node/e/7e334b5071e5b4486106b1fd returns the same record as sb.node.v1. Or call the get_entity MCP tool at https://sigb.ai/api/mcp with name kras.

{
  "name": "kras",
  "label": "KRAS",
  "asOf": "2026-11-10",
  "mentions": 146,
  "outlets": 103,
  "domains": 12,
  "node": {
    "id": "sb:e/7e334b5071e5b4486106b1fd",
    "schema": "sb.node.v1",
    "rest": "https://sigb.ai/api/v1/node/e/7e334b5071e5b4486106b1fd",
    "knowledgeCutoff": "2026-11-10T23:26:12.528504+00:00",
    "snapshot": "this deploy's committed data files (commit not exposed in this runtime)"
  },
  "coverageTrend": "fading",
  "history": {
    "since": "2026-11-04T13:04:02.304216+00:00",
    "changes": 0
  },
  "whereFrom": {
    "level": "counts",
    "label": "146 mentions across 12 domains",
    "children": [
      {
        "level": "reports",
        "label": "6 reports drawn on this page, each with its link",
        "children": {
          "count": 6,
          "unfold": "expand=+1"
        }
      },
      {
        "level": "domains",
        "label": "12 coverage domains",
        "children": {
          "count": 12,
          "unfold": "expand=+1"
        }
      },
      {
        "level": "not shown",
        "label": "The other 140 mentions",
        "edge": "counted daily from tracked coverage; single mentions are not listed one by one"
      }
    ]
  }
}

The figures on this page, as data. The tool returns the full entity record.

Events involving KRAS

Most-reported first, then newest. Registered events come from the event record; reported events are groups of claims about one occurrence. Claims are grouped when they were first reported within 2 days of each other and either name at least 2 of the same people, places or things besides this one, or share at least 25% of their wording. Each claim keeps its own record.

  • Sotorasib plus panitumumab extends progression-free survival in KRAS G12C-mutant colorectal cancer

    Reported claim · first reported 7 Nov 2026 · 1 claim · best-carried claim: 1 separate publisher

    could not check

  • How Does Divarasib Compare With Other KRAS Inhibitors in NSCLC? - Targeted Oncology

    Reported claim · first reported 5 Nov 2026 · 1 claim · best-carried claim: 2 separate publishers

    single source

  • Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC - OncLive

    Reported claim · first reported 4 Nov 2026 · 1 claim · best-carried claim: 2 separate publishers

    single source

Walk the record from KRAS

Open where it comes from, follow a claim or a related name, and use the trail to come back. Every step says what it is, how it stands and when. Machines read the same record.

KRAS

Entity.

Evidence
539 documents · 189 separate publishers · a mention shows the name is in use, not that any claim about it is true
Standing
A name from our starting list; its record is kept up to date automatically from coverage
Time
first seen 11 Mar 2026, last seen 9 Nov 2026
Measured
7% of mentions say something specific about it; the rest only name it
As of
10 Nov 2026
13 links from here

Who it moves with: the 10 names are in the map above.

What is claimed about it (3)

  • Single source: Reported by one source so far.
  • Could not check: We could not count this claim's sources, so we do not say how well it is supported.

Situations it is named in (0)

none on file at this cutoff

For machines: this record as JSON

Watch this

What the coverage says

Recent reporting that names KRAS, newest first. Open any row to follow it to the original article.

Evidence tiers: primary source = an official public record · attributed = a named outlet, receipt linked · lead = observed, not yet receipted.

What it connects to

Related records.

Recorded history

No change in coverage state or wire tier recorded since 4 Nov 2026.

Ask about KRASWatch KRAS

Story momentum counts mentions in tracked coverage. Prices are the market’s own, cited with the venue. Informational only, not advice. As of 10 Nov 2026.